Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1972 3
1973 2
1974 2
1975 2
1976 2
1977 12
1978 4
1979 10
1980 4
1981 7
1982 13
1983 8
1984 9
1985 6
1986 4
1987 13
1988 14
1989 4
1990 6
1991 11
1992 9
1993 5
1994 8
1995 8
1996 7
1997 14
1998 8
1999 6
2000 7
2001 6
2002 12
2003 8
2004 9
2005 11
2006 15
2007 11
2008 15
2009 18
2010 19
2011 17
2012 17
2013 15
2014 11
2015 22
2016 17
2017 14
2018 17
2019 18
2020 20
2021 16
2022 20
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

526 results

Results by year

Filters applied: . Clear all
Page 1
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators. Tashkin DP, et al. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.
Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.
McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HA, Barjaktarevic I, Barr RG, Bleecker ER, Boscardin J, Bowler RP, Buhr RG, Criner GJ, Comellas AP, Curtis JL, Dransfield M, Doerschuk CM, Dolezal BA, Drummond MB, Han MK, Hansel NN, Helton K, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Lazarus SC, Martinez FJ, Ohar J, Ortega VE, Paine R 3rd, Peters SP, Reinhardt JM, Rennard S, Smith BM, Tashkin DP, Couper D, Cooper CB, Woodruff PG. McKleroy W, et al. Among authors: tashkin dp. JAMA. 2023 Aug 1;330(5):442-453. doi: 10.1001/jama.2023.11676. JAMA. 2023. PMID: 37526720 Free PMC article.
Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Tashkin DP, et al. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi: 10.1056/NEJMoa055120. N Engl J Med. 2006. PMID: 16790698 Free article. Clinical Trial.
Marijuana and Lung Disease.
Tashkin DP. Tashkin DP. Chest. 2018 Sep;154(3):653-663. doi: 10.1016/j.chest.2018.05.005. Epub 2018 May 17. Chest. 2018. PMID: 29778658 Review.
Medicinal marijuana?
Tashkin DP, Roth MD, Dubinett SM. Tashkin DP, et al. N Engl J Med. 1997 Apr 17;336(16):1186; author reply 1186-7. N Engl J Med. 1997. PMID: 9102572 No abstract available.
Pulmonary effects of inhaled cannabis smoke.
Tashkin DP, Roth MD. Tashkin DP, et al. Am J Drug Alcohol Abuse. 2019;45(6):596-609. doi: 10.1080/00952990.2019.1627366. Epub 2019 Jul 12. Am J Drug Alcohol Abuse. 2019. PMID: 31298945 Review.
526 results